Dr. Shinichiro Kurosawa

Division of Graduate Medical Sciences

Boston University, USA





1984 Ph.D., Gunma University, School of Medicine, Maebashi, Japan; The Third Department of Internal Medicine

1979 M.D., Gunma University, School of Medicine, Maebashi, Japan

1975 Pre-Medicine, Gunma University, Maebashi, Japan


Publications (Selected)

  1. Kurosawa S., Matsuda M., and Aoki N.: Urinary procoagulant behaves as tissue factor by promoting factor VIIa-catalyzed activation of factor X. Thromb. Res. 3:595-606, 1984 (Impact Factor 2.803)
  2. Kurosawa S., Aoki N.: Preparation of thrombomodulin from human placenta. Thromb. Res. 37:353-364, 1985 (Impact Factor 1.153)
  3. Kurosawa S., Galvin J.B., Esmon N.L., and Esmon C.T.: Proteolytic formation and properties of functional domains of thrombomodulin. J. Biol. Chem. 262:22062212, 1987 (Impact Factor 7.199)
  4. Esmon C.T, Esmon N.L., Kurosawa S., and Johnson A.E.: Interaction of thrombin with thrombomodulin. In: Bioregulatory Functions of Thrombin (Annals of the New York Academy of Sciences) Vol. 485, pp. 215220, 1987
  5. Galvin J.B., Kurosawa S., Moore K, Esmon C.T., and Esmon N.L.: Reconstitution of rabbit thrombomodulin into phospholipid vesicles. J. Biol. Chem. 262:21992205, 1987 (Impact Factor 7.199)
  6. Kurosawa S., Stearns D.J., Jackson K.W., and Esmon C.T.: A 10-kDa cyanogen bromide fragment from the epidermal growth factor-homology domain of rabbit thrombomodulin contains the primary thrombin binding site. J. Biol. Chem. 263:5993-5996, 1988 (Impact Factor 7.199)
  7. Stearns D.J., Kurosawa S., Sims P.J., Esmon N.L., and Esmon C.T.: The interaction of a Ca2+ dependent monoclonal antibody with the protein C activation peptide region: evidence for obligatory Ca2+ binding to both antigen and antibody. J. Biol. Chem. 263:826-832, 1988 (Impact Factor 7.199)
  8. Kurosawa S.: The role of complex formation and epidermal growth factor-like domains in the regulation of blood coagulation by the thrombomodulin-protein C system. Acta Haematol. Jpn. 52: 1343-1349, 1989
  9. Stearns D., Kurosawa S., and Esmon C.T.: Micro-thrombomodulin: Residues 310-486 from the epidermal growth factor precursor-homology domain of thrombomodulin will accelerate protein C activation. J. Biol. Chem. 264:3352-3356, 1989 (Impact Factor 7.199)
  10. Kawakami M., Tsutsumi H., Kumakawa T., Abe H., Hirai M., Kurosawa S., Mori M., and Fukushima M.: Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood 76:1962-1964, 1990 (Impact Factor 8.372)
  11. Fukudome K., Kurosawa S., Stearns-Kurosawa D.J., He X., Rezaie A.R., and Esmon C.T.: The endothelial cell protein C receptor: Cell surface expression and direct ligand binding by the soluble receptor. J. Biol. Chem. 271:17491-17498, 1996 (Impact Factor 7.199)
  12. Regan L.M., Stearns-Kurosawa D.J., Kurosawa S., Mollica J., Fukudome K., and Esmon C.T.: The endothelial cell protein C receptor: Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors. J. Biol. Chem. 271:17499-17503, 1996 (Impact Factor 7.199)
  13. Stearns-Kurosawa D.J., Kurosawa S., Mollica J.S, Ferrell G.L., and Esmon C.T.: The endothelial cell protein C receptor augments protein C activation by the thrombinthrombomodulin complex. Proc. Natl. Acad. Sci. (USA) 93:10212-10216, 1996 (Impact Factor 9.821)
  14. Kurosawa S, Stearns-Kurosawa DJ, Hidari N, and Esmon CT: Identification of functional endothelial protein C receptor in human plasma. J. Clin. Invest. 100:411-418, 1997 (Impact Factor 9.315)
  15. Kurosawa S, Stearns-Kurosawa DJ, Carson CW, D’Angelo A, Della Valle P, and Esmon CT: Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: Lack of correlation with thrombomodulin suggests involvement of different pathological processes. Blood 91:725-727, 1998 (Impact Factor 8.372)
  16. Smirnov MD, Safa O, Regan L, Mather T, Stearns-Kurosawa DJ, Kurosawa S, Rezaie AR, Esmon NL, Esmon CT: A chimeric protein C containing the prothrombin Gla domain exhibits increased anticoagulant activity and altered phospholipid specificity. J. Biol. Chem. 273:9031-9040, 1998 (Impact Factor 7.199)
  17. Esmon C.T., Fukudome K., Mather T., Bode W, Regan L.M., Stearns-Kurosawa D.J., and Kurosawa S.: Inflammation, sepsis and coagulation. Haematologica 84:254-259, 1999. (Impact Factor 2.074)
  18. Esmon CT, Gu JM, Xu J, Qu D, Stearns-Kurosawa DJ, Kurosawa S. Regulation and functions of the protein C anticoagulant pathway. Haematologica 84:363-368, 1999. (Impact Factor 2.074)
  19. Esmon CT, Xu J, Gu J-M, Qu D, Laszik Z, Ferrell G, Stearns-Kurosawa DJ, Kurosawa S, Taylor FB Jr, Esmon NL: Endothelial protein C receptor. (ISTH State-of-the-Art). Thromb. Haemost. 82:251-258, 1999. (Impact Factor 4.983)
  20. Taylor FB Jr, Stearns-Kurosawa DJ, Kurosawa S, Ferrell G, Chang AC, Laszik Z, Kosanke S, Peer G, Esmon CT: The endothelial cell protein C receptor aids in host defense against E. coli sepsis. Blood 95: 1680-1686, 2000. (Impact Factor 8.977) (PMID: 10688824)
  21. Kurosawa S, Esmon CT, DJ Stearns-Kurosawa: The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18, J. Immunol 165:4697-4703, 2000. (Impact Factor 6.834) (PMID: 11035113)
  22. Stearns-Kurosawa DJ, Swindle K, D’Angelo A, Della Valle P, Fattorini A, Caron N,Grimaux M, Woodhams B, Kurosawa S. Plasma levels of endothelial protein C receptor respond to anticoagulant treatment. Blood, 99:526-530, 2002. (Impact Factor 8.977) (PMID: 11781234)
  23. Boomsma MM, Stearns-Kurosawa DJ, Stegeman CA, Raschi E, Meroni PL, Kurosawa S, Cohen Tervaert JW. Plasma levels of soluble endothelial cell protein C receptor in patients with Wegener’s granulomatosis. Clin Exp Immunol, 128: 187-194, 2002. (Impact Factor 2.305) (PMID: 12033194)
  24. Toshihiro Kaneko, DJ Stearns-Kurosawa, Fletcher Taylor, Jr., Michaele Twigg, Koichi Osaki, Gary T Kinasewitz, Glenn Peer, Shinichiro Kurosawa. Reduced neutrophil CD10 expression in non-human primates and humans after in vivo challenge with E.coli or lipopolysaccharide. Shock: 20, 130-137, 2003 (Impact Factor 2.542) (PMID: 12865656)
  25. Stearns-Kurosawa DJ, Burgin C, Parker D, Comp P, Kurosawa S. Bimodal Distribution of Soluble Endothelial Protein C Receptor Levels in Healthy Populations J. Thromb. Haemost, 1:855-856, 2003 (Impact Factor 4.831) (PMID: 12871429)
  26. Ireland H, Konstantoulas CJ, Cooper JA, Hawe E, Humphries SE, Mather H, Goodall AH, Hogwood J, Juhan-Vague I, Yudkin JS, di Minno G, Margaglione M, Hamsten A, Miller GJ, Bauer KA, Kim YT, Stearns-Kurosawa DJ, Kurosawa S. EPCR Ser219Gly: Elevated sEPCR, prothrombin F1 + 2, risk for coronary heart disease, and increased sEPCR shedding in vitro. Artherosclerosis, 183:283-292, 2005. (Impact Factor 3.777) (PMID: 15921688)
  27. Matsumoto T, Kaneko T, Wada H, Kobayashi T, Abe Y, Nobori T, Shiku H, Stearns-Kurosawa DJ, Kurosawa S. Proteinase 3 expression on neutrophil membranes from patients with infectious disease. Shock, 26:128-133, 2006. (Impact Factor 3.318) (PMID: 16878019)
  28. Stearns-Kurosawa DJ, Lupu F, Taylor FB Jr, Kinasewitz G, Kurosawa S. Sepsis and pathophysiology of anthrax in a non-human primate model. Am J Pathol, 169:433-444, 2006. (Impact Factor 5.917) (PMID: 16877346)
  29. Kinasewitz G, Stearns-Kurosawa DJ, Kurosawa S. Soluble Thrombomodulin: a sign of bad times. Crit Care Med, 36(3):985-7, 2008. (PMID: 18431290)
  30. Reiner, AP, Carty CL, Jenny NS, Nievergelt C, Cushman M, Stearns-Kurosawa DJ, Kurosawa S, Kuller LH, Lange LA. PROC, PROCR and PROS1 polymorphisms, plasma anticoagulant phenotypes, and risk of cardiovascular disease and mortality in older adults: the Cardiovascular Health Study, J Thromb Haemost, 6(10):1625-32, 2008 (PMID: 18680534)
  31. Matsumoto, T, Kaneko, T, Seto M, Wada H, Kobayashi T, Nakatani K, Tonomura H, Tono Y, Ohyabu M, Nobori T, Shiku H, Sudo A, Uchida A, [Stearns-]Kurosawa DJ, and Kurosawa S. The membrane proteinase 3 expression on neutrophils was downregulated after treatment with infliximab in patients with rheumatoid arthritis. Clin Appl Thromb Hemost, 14(2):186-92, 2008 (PMID: 18372277)
  32. Stearns-Kurosawa, DJ, Collins V, Freeman S, Tesh VL, Kurosawa S. Distinct Physiologic and Inflammatory Responses Elicited in Baboons after Challenge with Shiga Toxin Type 1 or 2 from Enterohemorrhagic Escherichia coli. Infect Immun 78(6):2497-2504, 2010.(PMID: 20308301)
  33. Stearns-Kurosawa, DJ, Osuchowski MF, Valentine C, Kurosawa S, Remick DG. The Pathogenesis of Sepsis. Annu Rev Pathol. 28;6:19-48, 2011 (PMID: 20887193)
  34. Stearns-Kurosawa D. J., Collins V., Freeman S., Debord D., Nishikawa K., Oh S, Leibowitz C. S., Kurosawa S., Rescue from lethal Shiga Toxin 2-induced renal failure with a cellpermeable peptide,Pediatr. Nephrol., 2011, 26:2031-9 (PMID: 2160390)
  35. Impaired function of the Tie-2 receptor contributes to vascular leakage and lethality in anthrax. Ghosh CC, Mukherjee A, David S, Knaus UG, Stearns-Kurosawa DJ, et al. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(25):10024-9.
  36. Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals. Mayer CL, Leibowitz CS, Kurosawa S, Stearns-Kurosawa DJ. Toxins. 2012; 4(11):1261-87.
  37. Comparison of disseminated intravascular coagulation in trauma with coagulopathy of trauma/acute coagulopathy of trauma-shock. Gando S, Wada H, Kim HK, Kurosawa S, Nielsen JD, et al. Journal of thrombosis and haemostasis : JTH. 2012; 10(12):2593-5.
  38. Plasma bacterial and mitochondrial DNA distinguish bacterial sepsis from sterile systemic inflammatory response syndrome and quantify inflammatory tissue injury in nonhuman primates. Sursal T, Stearns-Kurosawa DJ, Itagaki K, Oh SY, Sun S, et al. Shock (Augusta, Ga.). 2013; 39(1):55-62. NIHMSID: NIHMS419327
  39. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. Wada H, Thachil J, Di Nisio M, Mathew P, Kurosawa S, et al. Journal of thrombosis and haemostasis : JTH. 2013;
  40. Distinct renal pathology and a chemotactic phenotype after enterohemorrhagic Escherichia coli shiga toxins in non-human primate models of hemolytic uremic syndrome. Stearns-Kurosawa DJ, Oh SY, Cherla RP, Lee MS, Tesh VL, et al. The American journal of pathology. 2013; 182(4):1227-38.
  41. Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. Iskander KN, Osuchowski MF, Stearns-Kurosawa DJ, Kurosawa S, Stepien D, et al. Physiological reviews. 2013; 93(3):1247-88.
  42. The sepsis model: an emerging hypothesis for the lethality of inhalation anthrax.
  43. Coggeshall KM, Lupu F, Ballard J, Metcalf JP, James JA, et al. Journal of cellular and molecular medicine. 2013; 17(7):914-20. NIHMSID: NIHMS471923
  44. Quiescent complement in nonhuman primates during E coli Shiga toxin-induced hemolytic uremic syndrome and thrombotic microangiopathy. Lee BC, Mayer CL, Leibowitz CS, Stearns-Kurosawa DJ, Kurosawa S. Blood. 2013; 122(5):803-6.
  45. Harmonized guidance for disseminated intravascular coagulation from the International Society on Thrombosis and Haemostasis and the current status of anticoagulant therapy in Japan: a rebuttal. Wada H, Thachil J, Di Nisio M, Kurosawa S, Gando S, et al. Journal of thrombosis and haemostasis : JTH. 2013; 11(11):2078-9.
  46. Complement, thrombotic microangiopathy and disseminated intravascular coagulation. Kurosawa S, Stearns-Kurosawa DJ. Journal of intensive care. 2014; 2(1):65.
  47. Shiga toxin 2-induced endoplasmic reticulum stress is minimized by activated protein C but does not correlate with lethal kidney injury. Parello CS, Mayer CL, Lee BC, Motomochi A, Kurosawa S, et al., Toxins. 2015; 7(1):170-86.